The latest round of Big Pharma earnings calls delivered a sweeping look at the opportunities and challenges shaping the biopharma industry heading into the second half of 2026. Quarterly earnings seasons have
More
The Securities and Exchange Commission has unveiled a long-anticipated regulatory framework specifically designed for digital assets, marking a significant shift from decades of applying outdated securities rules to crypto markets. On August
More
The New Mexico Environment Department is seeking public input as it reviews exemptions under the state’s Per- and Polyfluoroalkyl Substances Protection Act. The department held a webinar on August 18, 2026, explaining
More
McKool Smith has moved decisively on associate compensation, raising salaries by between $10,000 and $20,000 effective January 1, ahead of many larger rivals. The Texas trial powerhouse acted while much of Biglaw
More
The FTSE 100 finished the week on a positive note on Friday, driven by stronger UK private sector activity and a surge in gold prices boosting mining stocks. The FTSE 100 index
More
Herbalife Nutrition has long been a prominent player in the personal care and nutritional supplements market, competing across a crowded global landscape. The company, traded on the New York Stock Exchange under
More
The Treasury Department’s move to calm government debt markets is generating unintended consequences, with investors increasingly pricing in higher inflation expectations. Breakeven rates, a market-based measure comparing Treasury yields to inflation-protected securities,
More
Gamma Communications (GAMA) shares jumped sharply higher on the FTSE 250 on news that the telecommunications company has entered into formal bid discussions. Takeover speculation has long surrounded Gamma, a business-to-business communications
More
Europe’s richest handicap, the Ebor at York, takes centre stage on Saturday afternoon with a highly competitive field set to do battle at 3.35pm. Ante-post punters who backed EMIT at 25/1 a
More
Lundbeck’s chief executive Charl van Zyl says the Danish neuroscience company is firmly on track to keep “punching above its weight” as a mid-cap challenger in the sector. The company posted sales
More